Dechra Pharmaceuticals (DPH LN)

Dechra Pharmaceuticals is a global specialist in the development, manufacture, and marketing of high-quality veterinary pharmaceuticals and related products, focusing on companion animals, equine, and food-producing animals. Key products include treatments for endocrinology, dermatology, and pain management, such as Vetoryl for Cushing's disease in dogs and Felimazole for hyperthyroidism in cats. The company was founded in 1997 and moved its global headquarters to Boston, Massachusetts, in June 2026.